EANS-Adhoc: SYGNIS Pharma AG / SYGNIS announces acquisition of a loan from BASF SE

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Contracts

29.06.2012

Ad-hoc release

SYGNIS announces acquisition of a loan from BASF SE

Heidelberg, 29 June 2012 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today announces the
execution of an agreement effective 31 March 2012 with BASF SE
to acquire a loan amounting to EUR 8,000,000 for a purchase
price of EUR 1.00 which equals the fair value of the loan. The
loan was granted to SYGNIS Bioscience GmbH & Co. KG, a
wholly-owned subsidiary of SYGNIS Pharma AG. The acquisition of the
loan is part of the necessary realignment of the Company. BASF is
a shareholder with approximately 11 per cent in SYGNIS Pharma AG.

The acquisition of the loan at fair value will be accounted through
profit and loss in the consolidated financial statements ended 31
March 2012.

The loan granted to SYGNIS Bioscience GmbH & Co. KG in September
2006 was due for repayment on 30 June 2015. Interest was charged at
the 3-month EURIBOR plus a customary mark-up.

For further information please contact:

|Peter Willinger |
|Co-CEO/CFO |
|Tel: +49 (0) 6221-454 836 |
|Email: willinger@sygnis.de |

### Disclaimer

This publication is intended for information only and constitutes
neither an offer to sell nor an invitation to buy securities. Some
statements included in this press release, relating neither to
proven financial results nor other historical data, should be
viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees
since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and
goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in
such statements. SYGNIS does not undertake to publicly update
or revise these statements in the light of new information or
future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English